EUVIMEDEUVIMED entdecken
Crossref

Antibody-Free Glycogen Nanoparticles Engage Human Immune T Cells for Intracellular Delivery of Small Drugs or mRNA

Soraia Fernandes, Miriam Quattrociocchi, Marco Cassani, Giulio Savazzi, Darryl Johnson iD, Giancarlo Forte, Frank Caruso iD, Francesca Cavalieri iD

ACS Nano · 22.10.2024 · 18 (42) · 28910-28923

DOI: 10.1021/acsnano.4c09156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 11.10.2024. Verfasst von Soraia Fernandes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, The University of Melbourne, Parkville 3010, Victoria, Australia. Hauptthemen laut MEDLINE: Nanoparticles, Glycogen, T-Lymphocytes, RNA, Messenger. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: British Heart Foundation, National Health and Medical Research Council, H2020 Marie Sklodowska-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cells play a major role in immune defense against viral infections and diseases such as cancer. Accordingly, developing nanoparticle (NP) systems to effectively deliver therapeutics to T cells is of interest. However, NP-mediated delivery of drugs to T cells is challenging because of the nonphagocytic nature of T cells. To engage T cells and induce cellular internalization, NPs are typically decorated with specific receptor-targeting antibodies, often using laborious and costly procedures. Herein, we report that natural glycogen NPs (i.e., nanosugars) with different sizes (20-80 nm) and surface charges (neutral and positively charged) engage Jurkat T cells, undergo intracellular trafficking, and release encapsulated drug without the use of receptor-targeting antibodies. Specifically, glycogen-resveratrol constructs are employed to reactivate HIV-1 latently infected Jurkat T cells (J-Lat A2) and trigger proviral expression. Both neutral and positively charged glycogen NPs engage with J-Lat A2 cells. Large (84 ± 29 nm) and positively charged (23 ± 5 mV) NPs, denoted phytoglycogen-ethylenediamine (PGEDA) NPs, readily associate with the cell membrane and are internalized (60%) in J-Lat A2 cells but remain confined in the endocytic vesicles, with moderate reactivation of latent HIV-1 (4.7 ± 0.5%). Conversely, small (21 ± 5 nm) and positively charged (10 ± 6 mV) NPs, bovine glycogen-EDA (BGEDA) NPs, associate slowly with T cells but show nearly 100% internalization and efficient endosomal escape properties, resulting in 1.5-fold higher reactivation of latent HIV-1 in T cells. PGEDA NPs and BGEDA NPs are also internalized by primary human T cells (>90% cell association) and enable the transfection of mRNA, with BGEDA NPs showing a 2-fold higher transfection than PGEDA NPs. This work highlights the potential of BGEDA NPs for the effective intracellular delivery of small-molecule drugs and mRNA in T cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesGlycogenT-LymphocytesRNA, MessengerHumansJurkat CellsHIV-1ResveratrolDrug Delivery SystemsParticle Size

Stichwörter der Autor:innen

endosomal escapeglycogen nanoparticleshuman immune T cellsmRNA deliveryresveratrol

Substanzen

GlycogenRNA, MessengerResveratrol

Autor:innen und Institutionen

  • Department of Chemical Engineering, The University of Melbourne, Parkville 3010, Victoria, Australia.
  • International Clinical Research Centre, St. Anne Hospital, 656 91 Brno, Czech Republic.
  • Materials Characterization and Fabrication Platform, Department of Chemical Engineering, The University of Melbourne, Parkville 3010, Victoria, Australia.
  • School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London SE5 9NU, U.K.
  • School of Science, RMIT University, Melbourne 3000, Victoria, Australia.
  • Dipartimento di Scienze e Tecnologie Chimiche, Universita di Roma "Tor Vergata", Via Della Ricerca Scientifica 1, 00133 Rome, Italy.

ORCID-Profile: Darryl Johnson, Frank Caruso, Francesca Cavalieri

Förderung

  • British Heart Foundation
  • National Health and Medical Research Council
  • H2020 Marie Sklodowska-Curie Actions
  • Australian Research Council
  • RMIT University

Zitieren

APA

Fernandes, S., Quattrociocchi, M., Cassani, M., Savazzi, G., Johnson, D., Forte, G., Caruso, F., & Cavalieri, F. (2024). Antibody-Free Glycogen Nanoparticles Engage Human Immune T Cells for Intracellular Delivery of Small Drugs or mRNA. ACS Nano, 18(42), 28910-28923. https://doi.org/10.1021/acsnano.4c09156

Vancouver

Fernandes S, Quattrociocchi M, Cassani M, Savazzi G, Johnson D, Forte G, et al. Antibody-Free Glycogen Nanoparticles Engage Human Immune T Cells for Intracellular Delivery of Small Drugs or mRNA. ACS Nano. 2024;18(42):28910-28923. doi:10.1021/acsnano.4c09156

BibTeX
@article{Fernandes2024,
  author = {Fernandes, Soraia and Quattrociocchi, Miriam and Cassani, Marco and Savazzi, Giulio and Johnson, Darryl and Forte, Giancarlo and Caruso, Frank and Cavalieri, Francesca},
  title = {Antibody-Free Glycogen Nanoparticles Engage Human Immune T Cells for Intracellular Delivery of Small Drugs or mRNA},
  journal = {ACS Nano},
  year = {2024},
  volume = {18},
  number = {42},
  pages = {28910--28923},
  doi = {10.1021/acsnano.4c09156}
}
Kostenlos starten →